PDCD1 and cancer: With respect to the former, myasthenia gravis, most commonly in cancer patients receiving the PD-1 antagonist, nivolumab (61–63), as well as autoimmune hemolytic anemia in those receiving either nivolumab or ipilimumab (64–67), represent documented examples of predominantly autoantibody-driven IRAEs.